I 
115TH CONGRESS 
1ST SESSION H. R. 4116 
To amend the Public Health Service Act to require reporting by drug manu-
facturers to increase transparency in drug pricing, and for other pur-
poses. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 25, 2017 
Mr. DOGGETT (for himself, Mr. CUMMINGS, Ms. DELAURO, Mr. ELLISON, Mr. 
POCAN, Mr. GRIJALVA, Mr. CICILLINE, Mr. COHEN, Mr. CONYERS, Mr. 
HIGGINS of New York, Ms. KAPTUR, Mr. NADLER, and Mr. RASKIN) in-
troduced the following bill; which was referred to the Committee on En-
ergy and Commerce 
A BILL 
To amend the Public Health Service Act to require reporting 
by drug manufacturers to increase transparency in drug 
pricing, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Transparent Drug 
Pricing Act of 2017’’. 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
SEC. 2. DRUG MANUFACTURER REPORTING. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 399V–7. DRUG MANUFACTURER REPORTING. 
‘‘(a) MANDATORY REPORTING.—A drug manufac-
turer shall submit to the Secretary and to Congress an 
annual report specifying with respect to the previous cal-
endar year (except as provided in subsection (d)(2))— 
‘‘(1) the total expenditures of the manufacturer 
on— 
‘‘(A) domestic and foreign drug research 
and development, including an itemized descrip-
tion of— 
‘‘(i) basic and preclinical research; 
‘‘(ii) clinical research, reported sepa-
rately for each clinical trial; 
‘‘(iii) development of alternative dos-
age forms and strengths for the drug mol-
ecule or combinations, including the mol-
ecule; 
‘‘(iv) other drug development activi-
ties, such as nonclinical laboratory studies 
and record and report maintenance; 
‘‘(v) pursuing new or expanded indica-
tions for such drug through supplemental 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
applications under section 505 of the Fed-
eral Food, Drug, and Cosmetic Act; 
‘‘(vi) carrying out postmarket require-
ments related to such drug, including 
under section 505(o)(3) of such Act; 
‘‘(vii) carrying out risk evaluation and 
mitigation strategies in accordance with 
section 505–1 of such Act; and 
‘‘(viii) marketing research; 
‘‘(B) the acquisition of drug components 
and packaging, in total and per unit sold, bro-
ken out by source and cost and identifying spe-
cific costs that reflect internal transfers within 
the manufacturer’s company; 
‘‘(C) other acquisitions relating to drugs, 
including for the purchase of patents and li-
censing or the acquisition of any corporate enti-
ty owning any rights to a drug during or after 
development of the drug; and 
‘‘(D) marketing, advertising, and educating 
for the promotion of a drug, including a break-
down of amounts aimed at consumers, pre-
scribers, managed care organizations, and oth-
ers, irrespective of whether a particular drug is 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
mentioned in the marketing, advertising, or 
educating; 
‘‘(2) the gross revenue, net revenue, gross prof-
it, and net profit of the manufacturer with respect 
to drugs; 
‘‘(3) the total number of units of each type of 
drug that were sold in interstate commerce; 
‘‘(4) pricing information with respect to the sale 
of drugs, including— 
‘‘(A) wholesale acquisition cost; 
‘‘(B) net average price realized by pre-
scription drug benefit managers for drugs pro-
vided to individuals in the United States, after 
accounting for any rebates or other payments 
from the manufacturer to the pharmacy benefit 
manager and from the pharmacy benefit man-
ager to the manufacturer; and 
‘‘(C) the net price of each drug, after ac-
counting for discounts, rebates, or other finan-
cial considerations, charged to purchasers in 
each applicable country of the Organisation for 
Economic Co-operation and Development; 
‘‘(5) any Federal benefits received by the manu-
facturer with respect to a drug, including the 
amounts and periods of impact for each such ben-
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
efit, including tax credits; Federal grants, including 
from the National Institutes of Health, the Depart-
ment of Defense, the Department of Energy, the 
Centers for Disease Control and Prevention, or other 
Federal departments or agencies; patent applications 
that benefitted from such grants; patent extensions; 
exclusivity periods; and waivers of fees; 
‘‘(6) the percentage of research and develop-
ment expenditures described in clauses (i) through 
(v) of paragraph (1)(A) that were derived from Fed-
eral funds; 
‘‘(7) executive compensation for the chief execu-
tive officer, chief financial officer, and the 3 other 
most highly compensated executive officers, includ-
ing bonuses, paid by such manufacturer, and stock 
options affiliated with the manufacturer that were 
offered to or accrued by such officers; and 
‘‘(8) any other information as the Secretary 
may require. 
‘‘(b) VOLUNTARY SUPPLEMENTAL REPORTING.—A 
drug manufacturer may supplement a report under sub-
section (a) with any additional information the manufac-
turer chooses to provide related to drug pricing decisions, 
such as— 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
‘‘(1) total expenditures on drug research, drug 
development, and clinical trials on drugs that failed 
to receive approval by the Food and Drug Adminis-
tration; and 
‘‘(2) a list of drugs and drug prices of other 
manufacturers for purposes of comparison with the 
manufacturer’s own drugs and drug prices. 
‘‘(c) SPECIAL RULE.—A drug manufacturer shall— 
‘‘(1) to the extent possible, disaggregate the in-
formation required to be reported by this section by 
the particular drug involved; and 
‘‘(2) submit all information required to be re-
ported by this section with respect to each applicable 
drug in a single annual report. 
‘‘(d) SUBMISSION OF REPORTS.— 
‘‘(1) IN GENERAL.— 
‘‘(A) SUBMISSION BY DRUG MANUFACTUR-
ERS.—Drug manufacturers shall submit the an-
nual reports required under this section to the 
Secretary in a usable format, as the Secretary 
may require. 
‘‘(B) COLLATION BY THE SECRETARY.— 
The Secretary shall collate the reports received 
as described in subparagraph (A) and submit 
such collated reports to Congress, together with 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
an analysis of the reports by the Secretary that 
includes— 
‘‘(i) a summary of data from the re-
ports; 
‘‘(ii) consideration of factors such as 
trends on research and development costs, 
Federal benefits, and manufacturer patient 
assistance programs; and 
‘‘(iii) the relationship between the fac-
tors described in clause (ii) and prescrip-
tion drug prices. 
‘‘(C) PUBLIC
AVAILABILITY.—The Sec-
retary shall make the reports submitted by 
manufacturers as described in subparagraph 
(A) and the collated reports together with the 
analysis of the Secretary described in subpara-
graph (B) publicly available, including by post-
ing such reports to the internet website of the 
Department of Health and Human Services, in 
a searchable format. 
‘‘(2) INITIAL REPORT.— 
‘‘(A) IN GENERAL.—A drug manufacturer 
shall submit an initial report pursuant to this 
section not later than one year after the date of 
enactment of the Transparent Drug Pricing Act 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
of 2017 (except as provided in subparagraph 
(B)). 
‘‘(B) 
REPORTING
PERIOD.—Notwith-
standing the requirement in subsection (a) that 
each report under such subsection be for the 
previous calendar year, the initial report of a 
drug manufacturer under subsection (a) shall 
include, for each drug marketed by the manu-
facturer, the information described in para-
graphs (1) through (6) of subsection (a) for the 
calendar year period beginning with the later 
of— 
‘‘(i) the calendar year in which the 
drug was approved under section 505 of 
the Federal Food, Drug, and Cosmetic 
Act, was licensed under section 351 of this 
Act, or received an exemption under sec-
tion 505(i) of the Federal Food, Drug, and 
Cosmetic Act or section 351(a)(3) of this 
Act; and 
‘‘(ii) the calendar year in which the 
manufacturer acquired the drug so ap-
proved, licensed, or exempted. 
‘‘(C) SMALL BUSINESSES.—In the case of 
a drug manufacturer that has fewer than 500 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS
drug (including a drug approved under subsection (c) or 
(j) of section 505 of the Federal Food, Drug, and Cos-
metic Act and a biological product licensed under sub-
section (a) or (k) of section 351 of this Act).’’. 
Æ 
VerDate Sep 11 2014 
22:29 Oct 26, 2017
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6301
E:\BILLS\H4116.IH
H4116
ethrower on DSK3G9T082PROD with BILLS